15 May 2024 - NICE has published final evidence-based recommendations on the use of selinexor (Nexpovio) in combination with bortezomib and dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma.

Selinexor, when used in combination with bortezomib and dexamethasone, is recommended for the treatment of adults with multiple myeloma if they have only had one previous line of treatment, and their condition is refractory to both daratumumab and lenalidomide, or they have only had two previous lines of treatment and their condition is refractory to lenalidomide.

Read NICE technology appraisal guidance